ASCO 2018: Targeted Therapies in Advanced Urothelial Cancer
Chicago, IL (UroToday.com) Evan Yu, MD, from the Fred Hutchinson Cancer Center provided a presentation of the role of precision therapy in the treatment of advanced urothelial cancer. RANGE was a phase III trial first presented at the ESMO 2017 Clinical Congress, a phase III randomized controlled trial assessing docetaxel with or without ramucirumab in platinum refractory advanced or metastatic urothelial carcinoma .
ASCO 2018: Results for 2nd-line Therapy: A Cross-over Trial, Abiraterone + Prednisone vs Enzalutamide for Patients Metastatic Castration-Resistant Prostate Cancer
Chicago, IL (UroToday.com) Enzalutamide and abiraterone have both been established as oral antiandrogen therapies which prolong overall survival in men with metastatic castration-resistant prostate cancer1,2. However, for patients who receive enzalutamide or abiraterone as first line therapy, only 15-30% of patients will respond to the alternate therapy, demonstrating that there is significant cross-resistance which occurs between enzalutamide and abiraterone3.
ASCO 2018: Immunotherapy-Based Approaches for Advanced Urothelial Cancer
Chicago, IL (UroToday.com) At the precision therapy for the treatment of advanced urothelial cancer session at ASCO 2018, Sandy Srinivas, MD, presented on the role of immunotherapy-based approaches in this disease space.
Starting with the FDA approval of cisplatin in 1978 for metastatic bladder cancer, there have been few exciting advances with regards to systemic therapy for bladder cancer until the recent approval of atezolizumab in 2016, quickly followed by four more immunotherapy options in 2017 (pembrolizumab, nivolumab, durvalumab, avelumab).
ASCO 2018: Active Surveillance in the Real World: What Have ProtecT and Other Prospective Trials Taught Us?
Chicago, IL (UroToday.com) Freddy Hamdy, MD, started the Precision Active Surveillance in Prostate Cancer session by discussing the role and impact of ProtecT and other prospective trials on how active surveillance is disseminated in the real world.
ASCO 2018: A Prospective Phase 2/3 Multicenter Study of 18F-DCFPyL PET/CT Imaging in Patients with Prostate Cancer: Examination of Diagnostic Accuracy (OSPREY)
Chicago, IL (UroToday.com) PET imaging has been slowly revolutionizing the management of prostate cancer, as it has been contributing to a chance in the definition of oligometastatic disease. Able to identify small volume metastatic disease, it has forced us to question prior management options for patients with previously diagnosed cM0 disease. However, in doing so, PET imaging has also begun to make its way into other stages of prostate cancer staging and management.
ASCO 2018: A Phase II Trial of Enzalutamide, Docetaxel and Androgen Deprivation Therapy (ENZADA) in Patients with Metastatic Castrate Sensitive Prostate Cancer (mCSPC)
Chicago, IL (UroToday.com) The management of advanced prostate cancer continues to change on an almost daily basis. From a time when docetaxel was the only management option for metastatic prostate cancer that had failed androgen deprivation therapy (ADT), we now have multiple treatment options (docetaxel/chemotherapy and androgen-receptor targeted therapies) that are competing for the same disease space. The shift now has moved towards combined therapies to overcome treatment resistance and improve survival outcomes greater than individual or sequenced therapies can.
ASCO 2018: The Association of BRCA1 and BRCA2 Mutations on Prostate Cancer Risk, Frequency, and Mortality: Systematic Review and Meta-Analysis
Chicago, IL (UroToday.com) The impact on genome alterations in DNA repair genes, including BRCA1 and BRCA2, have gained significant attention in the setting of prostate cancer in the past few decades. Patients with BRCA mutations appear to have more aggressive prostate cancer, as suggested by a few separate series and published studies. Family history of BRCA mutations is now an important clinical assessment as it may affect patient management.